MARKET

ACAD

ACAD

ACADIA Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

39.10
-1.12
-2.78%
After Hours: 39.53 +0.43 +1.10% 16:21 02/27 EST
OPEN
39.50
PREV CLOSE
40.22
HIGH
40.48
LOW
37.30
VOLUME
3.71M
TURNOVER
--
52 WEEK HIGH
53.70
52 WEEK LOW
21.56
MARKET CAP
6.00B
P/E (TTM)
-22.2387
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ACAD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ACAD stock price target is 55.80 with a high estimate of 70.00 and a low estimate of 40.00.

EPS

ACAD News

More
  • ACADIA (ACAD) Q4 Earnings Surpass, Nuplazid Drives Sales
  • Zacks · 5h ago
  • Cantor Fitzgerald Reiterates Overweight on ACADIA Pharmaceuticals, Raises Price Target to $75
  • Benzinga · 9h ago
  • Edited Transcript of ACAD earnings conference call or presentation 26-Feb-20 10:00pm GMT
  • Thomson Reuters StreetEvents · 13h ago
  • ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 16h ago

Industry

Biotechnology & Medical Research
-3.79%
Pharmaceuticals & Medical Research
-3.00%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About ACAD

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
More

Webull offers kinds of ACADIA Pharmaceuticals Inc. stock information, including NASDAQ:ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions.